JPWO2022020107A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2022020107A5
JPWO2022020107A5 JP2023504634A JP2023504634A JPWO2022020107A5 JP WO2022020107 A5 JPWO2022020107 A5 JP WO2022020107A5 JP 2023504634 A JP2023504634 A JP 2023504634A JP 2023504634 A JP2023504634 A JP 2023504634A JP WO2022020107 A5 JPWO2022020107 A5 JP WO2022020107A5
Authority
JP
Japan
Prior art keywords
exon
conjugate
antibody
complex
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023504634A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023535073A5 (https=
JP2023535073A (ja
JP7803926B2 (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/040998 external-priority patent/WO2022020107A1/en
Publication of JP2023535073A publication Critical patent/JP2023535073A/ja
Publication of JP2023535073A5 publication Critical patent/JP2023535073A5/ja
Publication of JPWO2022020107A5 publication Critical patent/JPWO2022020107A5/ja
Application granted granted Critical
Publication of JP7803926B2 publication Critical patent/JP7803926B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023504634A 2020-07-23 2021-07-09 ジストロフィン異常症を処置するための筋標的化複合体およびそれらの使用 Active JP7803926B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063055777P 2020-07-23 2020-07-23
US63/055,777 2020-07-23
US202063069077P 2020-08-23 2020-08-23
US63/069,077 2020-08-23
US202163143829P 2021-01-30 2021-01-30
US63/143,829 2021-01-30
PCT/US2021/040998 WO2022020107A1 (en) 2020-07-23 2021-07-09 Muscle targeting complexes and uses thereof for treating dystrophinopathies

Publications (4)

Publication Number Publication Date
JP2023535073A JP2023535073A (ja) 2023-08-15
JP2023535073A5 JP2023535073A5 (https=) 2024-07-18
JPWO2022020107A5 true JPWO2022020107A5 (https=) 2024-07-18
JP7803926B2 JP7803926B2 (ja) 2026-01-21

Family

ID=79728346

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023504634A Active JP7803926B2 (ja) 2020-07-23 2021-07-09 ジストロフィン異常症を処置するための筋標的化複合体およびそれらの使用

Country Status (11)

Country Link
US (1) US20230285586A1 (https=)
EP (1) EP4185330A4 (https=)
JP (1) JP7803926B2 (https=)
KR (1) KR20230044242A (https=)
CN (1) CN116368150A (https=)
AU (1) AU2021312709A1 (https=)
BR (1) BR112023001125A2 (https=)
CA (1) CA3186752A1 (https=)
IL (1) IL299662A (https=)
MX (1) MX2023000984A (https=)
WO (1) WO2022020107A1 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
US11168141B2 (en) 2018-08-02 2021-11-09 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US12097263B2 (en) 2018-08-02 2024-09-24 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US11911484B2 (en) 2018-08-02 2024-02-27 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US20220193250A1 (en) 2018-08-02 2022-06-23 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
EP3829595A4 (en) 2018-08-02 2022-08-24 Dyne Therapeutics, Inc. MUSCLE-DIRECTED COMPLEXES AND USES THEREOF IN THE TREATMENT OF DYSTROPHINOPATHIES
US12370264B1 (en) 2018-08-02 2025-07-29 Dyne Therapeutics, Inc. Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject
US12497615B2 (en) 2019-04-25 2025-12-16 Avidity Biosciences, Inc. Nucleic acid compositions and methods of multi-exon skipping
WO2022020108A1 (en) * 2020-07-23 2022-01-27 Dyne Therapeutics, Inc. Muscle-targeting complexes and uses thereof
US20240100177A1 (en) * 2020-12-04 2024-03-28 Dyne Therapeutics, Inc. Antibody-oligonucleotide complexes and uses thereof
WO2022270585A1 (ja) 2021-06-23 2022-12-29 日本新薬株式会社 アンチセンスオリゴマーの組み合わせ
IL309936A (en) * 2021-07-09 2024-03-01 Dyne Therapeutics Inc Muscle targeting complexes and formulations for the treatment of dystrophinopathy
US11638761B2 (en) 2021-07-09 2023-05-02 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
US11771776B2 (en) 2021-07-09 2023-10-03 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
EP4366783A4 (en) * 2021-07-09 2025-08-27 Dyne Therapeutics Inc MUSCLE TARGETING COMPLEXES AND THEIR USES FOR THE TREATMENT OF DYSTROPHINOPATHIES
CA3226300A1 (en) * 2021-07-09 2023-01-12 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US11672872B2 (en) 2021-07-09 2023-06-13 Dyne Therapeutics, Inc. Anti-transferrin receptor antibody and uses thereof
MX2024000490A (es) * 2021-07-09 2024-04-10 Dyne Therapeutics Inc Complejos dirigidos al musculo y usos de los mismos para tratar las distrofinopatías.
US11969475B2 (en) 2021-07-09 2024-04-30 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
KR20240032945A (ko) * 2021-07-09 2024-03-12 다인 세라퓨틱스, 인크. 근육 표적화 복합체 및 디스트로핀병증을 치료하기 위한 그의 용도
US11633498B2 (en) 2021-07-09 2023-04-25 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US20250339553A1 (en) 2022-04-15 2025-11-06 Dyne Therapeutics, Inc. Muscle targeting complexes and formulations for treating myotonic dystrophy
WO2024226471A2 (en) 2023-04-24 2024-10-31 Biomarin Pharmaceutical Inc. Compositions and methods for treating stxbp1 disorders
AU2024299328A1 (en) 2023-07-21 2026-01-22 Marrow Therapeutics, Inc. Hematopoietic cell targeting conjugates and related methods

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011130164A2 (en) * 2010-04-13 2011-10-20 The Regents Of The University Of California Unconjugated anti-tfr antibodies and compositions thereof for the treatment of cancer
PE20141114A1 (es) * 2010-12-20 2014-09-15 Genentech Inc Anticuerpos anti-mesotelina e inmunoconjugados
PT3097122T (pt) * 2014-01-24 2020-07-21 Ngm Biopharmaceuticals Inc Anticorpos de ligação de domínio 2 de beta klotho e métodos de utilização dos mesmos
TWI769982B (zh) * 2015-06-24 2022-07-11 日商Jcr製藥股份有限公司 通過血腦障壁之抗人類運鐵蛋白受體抗體
FR3049951A1 (fr) * 2016-04-12 2017-10-13 Univ Rabelais Francois Nouvelles constructions peptidiques et leur utilisation dans le traitement de la toxoplasmose
US20200282074A1 (en) * 2017-09-22 2020-09-10 Avidity Biosciences, Inc. Nucleic acid-polypeptide compositions and methods of inducing exon skipping
AR126019A1 (es) * 2018-05-30 2023-09-06 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
EP3829595A4 (en) * 2018-08-02 2022-08-24 Dyne Therapeutics, Inc. MUSCLE-DIRECTED COMPLEXES AND USES THEREOF IN THE TREATMENT OF DYSTROPHINOPATHIES
WO2020028842A1 (en) * 2018-08-02 2020-02-06 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating hypertrophic cardiomyopathy
GB2595980B (en) * 2019-01-04 2023-06-14 Marengo Therapeutics Inc Anti-TCR antibody molecules and uses thereof
JP7780691B2 (ja) * 2020-01-10 2025-12-05 ダイン セラピューティクス,インコーポレーテッド ジストロフィン異常症を処置するための筋標的化複合体およびそれらの使用
CN116348138A (zh) * 2020-07-23 2023-06-27 达因疗法公司 抗转铁蛋白受体(tfr)抗体及其用途
WO2022020108A1 (en) * 2020-07-23 2022-01-27 Dyne Therapeutics, Inc. Muscle-targeting complexes and uses thereof

Similar Documents

Publication Publication Date Title
JPWO2022020107A5 (https=)
JP2024160045A5 (https=)
JP2021533197A5 (https=)
JPWO2020028832A5 (https=)
JP2025067909A5 (https=)
JP2021533200A5 (https=)
JP2021532831A5 (https=)
JP2023015095A5 (https=)
JP2021533199A5 (https=)
IL309937A (en) Muscle targeting complexes and uses thereof for treating dystrophinopathies
JP2021533198A5 (https=)
IL309935A (en) Muscle targeting complexes and uses thereof for treating dystrophinopathies
IL309911A (en) Muscle targeting complexes and uses thereof for treating dystrophinopathies
JPWO2021142307A5 (https=)
IL309909A (en) Muscle targeting complexes and uses thereof for treating dystrophinopathies
IL309912A (en) Muscle targeting complexes and their uses for the treatment of dystrophinopathy
JPWO2021142227A5 (https=)
JP2021532832A5 (https=)
CA3226301A1 (en) Muscle targeting complexes and uses thereof for treating myotonic dystrophy
JPWO2020028857A5 (https=)
JPWO2020028864A5 (https=)
JPWO2023283615A5 (https=)
JP2026503873A (ja) Dmd遺伝子のエクソン45をスキップするための筋肉標的化複合体およびその使用
JPWO2021142313A5 (https=)
JPWO2022026152A5 (https=)